Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate.

The rights will be transferred from Corxel Pharmaceuticals, which had offered Cytokinetics up to $200 million in biobucks for regional rights to aficamten in 2020.